| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/02/2009 | CN101590229A Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| 12/02/2009 | CN101590223A SOD complex capsule and preparation method thereof |
| 12/02/2009 | CN101590222A SOD cell repair liquid and preparation method thereof |
| 12/02/2009 | CN101590221A Oral insulin medicament and preparation method thereof |
| 12/02/2009 | CN101590220A Method for preparing interferon liposome injection |
| 12/02/2009 | CN101590219A Refined earthworm protein polypeptide preparation |
| 12/02/2009 | CN101590079A Calcium supplement health care product and production method thereof |
| 12/02/2009 | CN101590078A Anticancer healthcare medicinal granules and production method thereof |
| 12/02/2009 | CN101590057A Antitumor compositions containing taxane derivatives |
| 12/02/2009 | CN101590011A Sustained release of peptides from pharmaceutical compositions |
| 12/02/2009 | CN100564524C Factor involved in metastasis and uses thereof |
| 12/02/2009 | CN100564517C Anti-glioma peptide of scorpion, preparation method and application thereof |
| 12/02/2009 | CN100564393C Separation of polypeptides comprising a racemized amino acid |
| 12/02/2009 | CN100563717C Application of LYRM1 gene in preparing medicament for promoting fat cell proliferation |
| 12/02/2009 | CN100563712C Liquid formulations of tumor necrosis factor-binding proteins |
| 12/02/2009 | CN100563709C Novel targeted tissue factor antibody as anticoagulants |
| 12/02/2009 | CN100563707C Activation and inhibition of the immune system |
| 12/02/2009 | CN100563656C Tamper-resistant oral opioid agonist |
| 12/02/2009 | CN100563465C Active nutritious health oral liquid of donkey-hide gelatin |
| 12/01/2009 | USRE41028 Administering a trefoil protein for treatment to the injury of the corneal epitheliuim; wound healing agents; spasmolytic peptide (SP), pS2, and active fragments; nonhydrolyzing;enzyme resistance; surgery; chemical exposure; ultraviolet radiation exposure; antiulcer agents |
| 12/01/2009 | US7626023 Compounds for treating tumors |
| 12/01/2009 | US7626008 Anti-angiogenic polypeptides |
| 12/01/2009 | US7626003 Genetically engineered cDNA of rat bcl-x gene and an improved protein |
| 12/01/2009 | US7626002 Cytokine zalpha11 ligand antibodies |
| 12/01/2009 | US7625998 Human growth hormone domains |
| 12/01/2009 | US7625996 Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol) |
| 12/01/2009 | US7625995 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same |
| 12/01/2009 | US7625875 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| 12/01/2009 | US7625870 Ala-Glu-Asp-Leu tetrapeptide of sequence 1; no side effects observed during long term administration; nontoxic; bronchitis, emphysema, asthma, COPD |
| 12/01/2009 | US7625869 modified metastin containing aza-glycine, methyl arginine and N-acetyl tyrosine amino acids; cancer metastasis suppressing activity, a cancer growth suppressing activity |
| 12/01/2009 | US7625867 BMP-3 propeptides and related methods |
| 12/01/2009 | US7625866 Increased content of high molecular weight multimers; hemophilia and blood disorder treatment |
| 12/01/2009 | US7625865 Insulin highly respirable microparticles |
| 12/01/2009 | US7625864 Mixture with a cyclic 3', 5'-adenylic acid modulator such as forskolin, activators of adenylate cyclase or macrophages, macrophage-derived factors that stimulate cAMP, calcium ionophores, inhibitors of phosphodiesterase or beta-2-adrenoreceptor or vasoactive intestinal peptide; optional axogenic factor |
| 12/01/2009 | US7625863 Treatment of patients with dysfunctional cardiac sodium channels |
| 12/01/2009 | US7625862 Method for making a high oxygen affinity modified hemoglobin for oxygen transport |
| 12/01/2009 | US7625861 Copolymer-1 improvements in compositions of copolymers |
| 12/01/2009 | US7625860 Administering a combination of a cytotoxic agent and a fibroblastic growth factor antagonist, wherein the FGF antagonist enhances the efficacy of the cytotoxic agent |
| 12/01/2009 | US7625859 HER-2 binding antagonists |
| 12/01/2009 | US7625759 For treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation |
| 12/01/2009 | US7625751 WNV core protein/capsid interacting protein and uses of the same |
| 12/01/2009 | US7625750 Compositions for DNA mediated gene silencing |
| 12/01/2009 | US7625734 Glutamine:fructose-6-phosphate amidotransferase (GFAT) comprising an internal purification marker and use thereof for the screening of compounds |
| 12/01/2009 | US7625716 Methods for assessing p19-Arf interactions in cMyc |
| 12/01/2009 | US7625715 HIN-1, a tumor suppressor gene |
| 12/01/2009 | US7625713 Process for identifying a ligand that binds to the NEP binding site for the SMR1 pentapeptide |
| 12/01/2009 | US7625711 Screening method for the identification of a drug for the development of an agent for prevention and/or treatment of Alzheimer's disease |
| 12/01/2009 | US7625710 Methods for determining 2F1-binding compounds |
| 12/01/2009 | US7625709 Reducing NgR-p75 mediated inhibition of axon regeneration |
| 12/01/2009 | US7625584 Isolating and stabilizing antihemophila factor for use in dosage cancentration for treatment of hemophlia |
| 12/01/2009 | US7625582 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 12/01/2009 | US7625573 Immunology active materials; anticancer agents, infections, autoimmune diseases, parasiticides; lipid bilayer with antitumor agent |
| 12/01/2009 | US7625565 Antiviral compositions comprising lysine-rich histone fractions prepared by pepsin treatment of thymic cell nuclei |
| 12/01/2009 | US7625558 Anticancer agents; administering nucleic acid which dimerizes with protein |
| 12/01/2009 | US7625555 Recombinant human interferon-like proteins |
| 12/01/2009 | US7625554 Treatment of alzheimer's disease |
| 12/01/2009 | US7625553 Method of treating cancer by administering an epithelum-derived T-cell factor |
| 12/01/2009 | US7625552 Bioactive polymers for imparting bioactive character to hydrophobic medical article surfaces |
| 12/01/2009 | CA2444590C Stabilized hemoglobin solutions |
| 12/01/2009 | CA2407210C Liposome drug delivery |
| 12/01/2009 | CA2376593C Method of particle formation |
| 12/01/2009 | CA2305533C Multilamellar coalescence vesicles (mlcv) containing biologically active compounds |
| 12/01/2009 | CA2265547C Method of treating endothelial injury |
| 12/01/2009 | CA2208503C Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
| 12/01/2009 | CA2154163C Ligand antagonists for treatment of breast cancer |
| 12/01/2009 | CA2107513C Fusion protein for prodrug activation |
| 11/26/2009 | WO2009143526A1 Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
| 11/26/2009 | WO2009143493A2 MODULATORS OF TNFα-DEPENDENT SIGNALING PATHWAYS AND USES THEREOF |
| 11/26/2009 | WO2009143489A2 Modulation of angiogenesis by a-beta peptide fragments |
| 11/26/2009 | WO2009143483A2 PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION |
| 11/26/2009 | WO2009143429A2 Vegf165 delivered by fibrin sealant to reduce tissue necrosis |
| 11/26/2009 | WO2009143380A2 Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
| 11/26/2009 | WO2009143367A2 Egf-a domain-mediated modulation of pcsk9 |
| 11/26/2009 | WO2009143356A1 Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |
| 11/26/2009 | WO2009143285A2 Exendins to lower cholestrol and triglycerides |
| 11/26/2009 | WO2009143280A2 Nanolipoprotein particles and related compositions, methods and systems |
| 11/26/2009 | WO2009143268A2 Treatment of mitochondrial diseases with an erythropoietin mimetic |
| 11/26/2009 | WO2009143141A1 Method for treating cd40-mediated diseases |
| 11/26/2009 | WO2009143133A2 Compositions and methods to protect cells by blocking entry of pathogen proteins |
| 11/26/2009 | WO2009143023A2 Neoplasia targeting peptides and methods of using the same |
| 11/26/2009 | WO2009142842A2 Novel macrocyclic inhibitors of hepatitis c virus replication |
| 11/26/2009 | WO2009142761A1 Caspofungin bo free of caspofungin co |
| 11/26/2009 | WO2009142759A1 Novel soluble cd83 polypeptides, formulations and methods of use |
| 11/26/2009 | WO2009142727A2 Sequence modified calcitonin gene related peptides (cgrp) |
| 11/26/2009 | WO2009142679A2 Methods for treating acute myocardial infarction |
| 11/26/2009 | WO2009142319A1 Vascular aging inhibitor and anti-aging formulation |
| 11/26/2009 | WO2009142195A1 Agent for induction/maintenance of remission |
| 11/26/2009 | WO2009141965A1 Filtration method |
| 11/26/2009 | WO2009141826A2 Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
| 11/26/2009 | WO2009141731A2 The large form of human 2', 5'-oligoadenylate synthetase oas3 for preventing or treating infection with positive-sense single-stranded rna viruses |
| 11/26/2009 | WO2009141621A1 Histamine binding protein |
| 11/26/2009 | WO2009141441A1 Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma |
| 11/26/2009 | WO2009141433A1 Low viscosity compositions comprising a pegylated gla-domain containing protein |
| 11/26/2009 | WO2009141418A1 Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative |
| 11/26/2009 | WO2009141264A2 Gallidermin to treat infections of the respiratory tract |
| 11/26/2009 | WO2009141257A1 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer |
| 11/26/2009 | WO2009141240A1 Novel dual targeting antitumoural conjugates |
| 11/26/2009 | WO2009141239A1 A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| 11/26/2009 | WO2009140833A1 Collagen peptide having immunoenchancing activity from cyanea nozakii and preparation method and uses thereof |
| 11/26/2009 | WO2009140765A1 Selective caspase inhibitors and uses thereof |